ライフサイエンスコーパス: hepatitis C

1 -up, which has reduced the burden of chronic hepatitis C.

2 rted 252 (134-389) deaths related to chronic hepatitis C.

3 tial progress in the path toward eliminating hepatitis C.

4 hosis (N = 25) had higher HIV-1 RNA and more hepatitis C.

5 , followed by cryptogenic cirrhosis (14.5%), hepatitis C (13.4%), and non-alcoholic fatty liver disea

6 ncluded non-alcoholic liver disease (58.0%), hepatitis C (26.0%), hepatitis B (10.0%), and alcohol (6

7 d the highest rate of endocarditis (16%) and hepatitis C (44%).

8 vs 18.5%, RR: 3.7, CI: 3.1-4.4), those with hepatitis C (54.7% vs 6.4%, RR: 8.5, CI: 6.5-11.3), and

9 8.5%; RR, 3.7 [95% CI, 3.1-4.4]), those with hepatitis C (54.7% vs 6.4%; RR, 8.5 [95% CI, 6.5-11.3]),

10 several forms of chronic liver disease like hepatitis C and alcohol cirrhosis.

11 Hepatitis C virus (HCV) causes acute hepatitis C and can lead to life-threatening complicatio

12 adjustment for age, gender, smoking status, hepatitis C and hepatitis B virus coinfection, group of

13 Treatment of patients coinfected with hepatitis C and human immunodeficiency viruses (HCV; HIV

14 21 male) initiating IFN-alpha treatment for Hepatitis-C and 30 (mean 50.4 +/- 15.7 years, 10 male) a

15 latform to model specific virus types (e.g., hepatitis C) and add additional cellular mechanisms (tis

16 and 75.1% among persons with hepatitis B or hepatitis C, and 22.6% and 25.9% among the immunization

17 now effective treatments for hepatitis B and hepatitis C, and follow-up after effective treatment sho

18 itis C treatment with potential to eliminate hepatitis C as a public health threat.

19 Long-term CVE (HR, 2.12; 95% CI, 1.24-3.61), hepatitis C as the etiology of liver disease (HR, 2.18;

20 at high-risk settings identified significant hepatitis C burden and reflex testing outperformed point

21 a launched a national programme to eliminate hepatitis C by 2020 (90% reduction in prevalence) throug

22 le interval 30-44), the incidence of chronic hepatitis C by 37% (29-44), and chronic hepatitis C mort

23 have reduced the prevalence of adult chronic hepatitis C by a median 37% (95% credible interval 30-44

24 hepatic fibrosis and inflammation in chronic hepatitis C (CHC) patients after eradication with direct

25 ion and liver disease progression in chronic hepatitis C (CHC) patients with T2D.

26 tabolic and inflammatory outcomes in chronic hepatitis C (CHC) patients: low-density lipoprotein (LDL

27 d focus on women reporting drug use and with hepatitis C co-infection.

28 ncidence rates of participants in the German hepatitis C cohort (GECCO) and compared our data to prev

29 in treatment-naive participants in the Swiss Hepatitis C Cohort Study.

30 d focus on women reporting drug use and with hepatitis C coinfection.

31 el of HCV disease progression and treatment (hepatitis C cost-effectiveness model: HEP-CE).

32 g Interferon-alpha (IFN-alpha) treatment for Hepatitis-C develop major depressive disorder (MDD).

33 previously postulated that the FDA-approved hepatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) might

34 try of Georgia embarked on the world's first hepatitis C elimination program.

35 Georgia's hepatitis C elimination programme has achieved substanti

36 n screening and treatment to achieve the WHO hepatitis C elimination target of an 80% reduction in in

37 eveloped a transmission model to capture the hepatitis C epidemic in Georgia, calibrated to data from

38 ceived a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 2015 and who did not have

39 oduced global targets for the elimination of hepatitis C (HCV) by 2030.

40 BM) are a key population affected by HIV and hepatitis C (HCV) co-infection.

41 nt of human immunodeficiency virus (HIV) and hepatitis C (HCV) coinfected patients with advanced live

42 A hepatitis C (HCV) cure is associated with changes in lip

43 atment options are limited for patients with hepatitis C (HCV) infection with treatment failure after

44 possible links between DO and autoimmunity, Hepatitis C (HCV) infection, and cancer, but the mechani

45 of these programs on the rate of new HIV and Hepatitis C (HCV) infections remains unknown as high mor

46 t of removing fibrosis stage restrictions on hepatitis C (HCV) treatment initiation rates among peopl

47 Yet, hepatitis C (HCV)-infected liver transplant (LT) patient

48 itis B (HR for NHW 1.35; 95% CI, 0.98-1.87), hepatitis C (HR for NHW 1.21; 95% CI, 1.06-1.38), and no

49 f this program led to efficient treatment of hepatitis C in a real-world population with a majority o

50 estimated 150 000 adults living with chronic hepatitis C in Georgia, 52 856 (35.1%) were diagnosed, 4

51 a focus on practical tools for management of hepatitis C in majority of currently infected individual

52 egies to scale up screening and treatment of hepatitis C in Pakistan and determine what is required t

53 000) treatments started annually, decreasing hepatitis C incidence by 26.5% (22.5-30.7) over 2018-30.

54 up screening and treatment to reduce global hepatitis C incidence by 80% by 2030, but little is know

55 Decreasing hepatitis C incidence by 80% is estimated to require a d

56 timated in terms of the relative decrease in hepatitis C incidence, prevalence, and mortality relativ

57 HIV acquisition (aOR, 2.2; 95% CI, 1.3-3.9), hepatitis C infection (aOR, 1.9; 95% CI, 1.1-3.4), black

58 f care in our model begins with diagnosis of hepatitis C infection through antibody screening and RNA

59 ed mortality, increased incidence of HIV and hepatitis C infection, poor mental health (suicidality,

60 Increases in fatal drug poisonings and hepatitis C infections associated with the opioid epidem

61 g viral infections such as HIV, hepatitis B, hepatitis C, influenza, and SARS-CoV-2.

62 Hepatitis C is a global health problem, and an estimated

63 m, including tuberculosis (TB), hepatitis B, hepatitis C, malaria, strongyloidiasis, schistosomiasis,

64 onic hepatitis C by 37% (29-44), and chronic hepatitis C mortality by 14% (3-30) and have prevented 3

65 likely obese, black, hypertensive, diabetic, hepatitis C positive, smokers, Public Health Service - I

66 substance use treatment or primary care with hepatitis C prescribers.

67 ad rheumatoid arthritis, multiple sclerosis, hepatitis C, psoriasis, psoriatic arthritis, Crohn's dis

68 act of donor age was strong in patients with hepatitis C-related cirrhosis (HR, 1.013; P < 0.001), su

69 60-2015 (including population growth) and to hepatitis C seroprevalence data from a national survey i

70 ys among people who inject drugs (PWID), and hepatitis C seroprevalence trends among blood donors.

71 The effectiveness of hepatitis C testing and linkage-to-care (LTC) is poorly

72 ) is essential for the management of chronic hepatitis C therapy.

73 enous pressure gradient (HVPG) after cure of hepatitis C translates into a clinical benefit.

74 HCV/HIV co-infected individuals to Eliminate Hepatitis C transmission) was an implementation trial pr

75 The Novel Model of Hepatitis C Treatment as an Anchor to Prevent HIV, Initi

76 tion-level effectiveness of these oral DAAs, hepatitis C treatment by a wide range of providers in di

77 ative scenarios for scaling up screening and hepatitis C treatment in 2018-30.

78 eported in liver transplantation and chronic hepatitis C treatment outcomes.

79 We provide a clinical review of hepatitis C treatment with a focus on practical tools fo

80 tivirals (DAAs) have ushered in a new era of hepatitis C treatment with potential to eliminate hepati

81 pangenotypic regimen suitable for mass-scale hepatitis C treatment, especially in resource-limited co

82 epatitis C with cost data on diagnostics and hepatitis C treatment.

83 ong treatment-naive individuals with chronic hepatitis C viral (HCV) infection and without cirrhosis,

84 g the molecular structures and activities of hepatitis C viral inhibitors and comparing hepatitis C v

85 Baseline characteristics, hepatitis C viral load (VL), genotypes, liver enzymes an

86 Hearts and lungs from donors with hepatitis C viremia are typically not transplanted.

87 due to hepatitis B virus (12.2 million) and hepatitis C virus (10.4 million), liver cancer due to he

88 core antibody (anti-HBc), antibodies against hepatitis C virus (anti-HCV).

89 id agonist therapy (OAT) reduces the risk of hepatitis C virus (HCV) acquisition among people who inj

90 Microelimination of hepatitis C virus (HCV) among people living with human i

91 Patients with hepatitis C virus (HCV) and advanced fibrosis remain at

92 Hepatitis C virus (HCV) and alcohol use are patient risk

93 obtained from unrelated cases infected with hepatitis C virus (HCV) and compared its performance wit

94 Hepatitis C virus (HCV) and hepatic dysfunction are asso

95 eath and tumoral recurrence in patients with hepatitis C virus (HCV) and hepatocellular carcinoma (HC

96 Patients were tested for HBV, hepatitis C virus (HCV) and HIV.

97 cure for patients chronically infected with hepatitis C virus (HCV) and improved post-liver transpla

98 ) can be used to circumvent these issues for hepatitis C virus (HCV) and norovirus.

99 e who inject drugs have a high prevalence of hepatitis C virus (HCV) and significant disease associat

100 Hepatitis C virus (HCV) and the opioid epidemic dispropo

101 pendency is a hallmark of the human pathogen hepatitis C virus (HCV) and was also described for the r

102 Hepatitis C virus (HCV) antigen testing is less expensiv

103 We investigated antibody responses to hepatitis C virus (HCV) antigens E1 and E2 and the relev

104 Immune-competent animal models for the hepatitis C virus (HCV) are nonexistent, impeding studie

105 Hepatitis C virus (HCV) as indication for LT decreased s

106 who inject drugs (PWID) have had the highest hepatitis C virus (HCV) burden; however, young PWID now

107 We constructed a hepatitis C virus (HCV) care cascade for adults in Georg

108 For example, hepatitis C virus (HCV) causes a specific, large-fold in

109 Hepatitis C virus (HCV) causes acute hepatitis C and can

110 Here, we show that hepatitis C virus (HCV) co-opts the host protein CypA to

111 years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.2 among HCV mo

112 mation in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection increases cognitive

113 -associated substitutions (RAS) could hamper hepatitis C virus (HCV) cure rates and elimination effor

114 (OAT) and compared once-daily to twice-daily hepatitis C virus (HCV) direct-acting antiviral (DAA) th

115 Hepatitis C virus (HCV) direct-acting antivirals are hig

116 Hepatitis C virus (HCV) disproportionately affects disad

117 the long-term outcomes in hepatitis B (HBV)/hepatitis C virus (HCV) dual-infected patients after ant

118 ose, human immunodeficiency virus (HIV), and hepatitis C virus (HCV) due to injection drug use (IDU)

119 iological function for the p7 viroporin from hepatitis C virus (HCV) during virus entry, but also ena

120 The World Health Organization's (WHO) hepatitis C virus (HCV) elimination target of an 80% red

121 To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it is essen

122 Most U.S. children with perinatal hepatitis C virus (HCV) exposure fail to receive the rec

123 y and safety in a phase IIa study in chronic hepatitis C virus (HCV) genotype (GT)-1-infected patient

124 Hepatitis C virus (HCV) genotype 4 is highly heterogeneo

125 s in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6.

126 of-life (HRQL) improvements in patients with hepatitis C virus (HCV) has been generally accepted.

127 Mortality associated with hepatitis C virus (HCV) has been well-documented nationa

128 k of immunocompetent small animal models for hepatitis C virus (HCV) has greatly hindered the develop

129 e and safe direct-acting antivirals to treat hepatitis C virus (HCV) has resulted in greater ease and

130 y effective direct-acting antivirals against Hepatitis C virus (HCV) have created an opportunity to t

131 Direct-acting antivirals (DAAs) targeting hepatitis C virus (HCV) have revolutionized outcomes in

132 cting antiviral therapy is expected to abate hepatitis C virus (HCV) incidence among human immunodefi

133 Hepatitis C virus (HCV) incidence has increased in the w

134 Micro-elimination of the hepatitis C virus (HCV) includes treatment in population

135 Hepatitis C virus (HCV) infection among maintenance hemo

136 g for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection among persons who inje

137 Kidneys from donors with hepatitis C virus (HCV) infection are traditionally cons

138 lth Organization has set a goal to eliminate hepatitis C virus (HCV) infection as public health threa

139 al natural killer (NK) cell responses during hepatitis C virus (HCV) infection can be restored after

140 Since 2002, a global epidemic of acute hepatitis C virus (HCV) infection has been noted in men

141 t of direct-acting antiviral agents to treat hepatitis C virus (HCV) infection has raised the possibi

142 Chronic hepatitis C virus (HCV) infection in Asia is characteriz

143 Treatment uptake for hepatitis C virus (HCV) infection in people who inject d

144 Most persons with chronic hepatitis C virus (HCV) infection in the United States a

145 though curative therapy is now available for hepatitis C virus (HCV) infection in the United States,

146 resulted in an increase in organ donors with hepatitis C virus (HCV) infection in the United States.

147 Liver disease as a result of chronic hepatitis C virus (HCV) infection is a global problem.

148 Chronic hepatitis C virus (HCV) infection is a leading cause of

149 BACKGROUNDChronic hepatitis C virus (HCV) infection is characterized by a

150 Chronic hepatitis C virus (HCV) infection is characterized by ac

151 Chronic hepatitis C virus (HCV) infection is characterized by pe

152 Hepatitis C virus (HCV) infection is common among people

153 Hepatitis C virus (HCV) infection is highly prevalent am

154 Chronic hepatitis C virus (HCV) infection is one of the major ca

155 Hepatitis C virus (HCV) infection is the main cause of h

156 Untreated, chronic hepatitis C virus (HCV) infection may lead to progressiv

157 A comprehensive strategy to control hepatitis C virus (HCV) infection needs a vaccine.

158 croglobulin and CD40 antigen and presence of hepatitis C virus (HCV) infection predicted early (year

159 Hepatitis C virus (HCV) infection promotes hepatocyte gr

160 in nuclear morphology of liver cells due to hepatitis C virus (HCV) infection using this model.

161 erum aspartate aminotransferase (AST) value, Hepatitis C virus (HCV) infection, alcohol abuse, CD4/CD

162 abase was used to identify adults with NASH, hepatitis C virus (HCV) infection, and alcohol-related l

163 ldren under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently n

164 Despite recent breakthroughs in treatment of hepatitis C virus (HCV) infection, we have limited under

165 CD4+ T cell failure is a hallmark of chronic hepatitis C virus (HCV) infection.

166 direct-acting antiviral treatment (DAA) for hepatitis C virus (HCV) infection.

167 million people are chronically infected with hepatitis C virus (HCV) infection.

168 sing outcomes using kidneys from donors with hepatitis C virus (HCV) infection.

169 transmission is the major cause of pediatric hepatitis C virus (HCV) infection.

170 Sexually transmitted acute hepatitis C virus (HCV) infections (AHIs) have been main

171 Increasing numbers of hepatitis C virus (HCV) infections among men who have se

172 FDA-approved drug used for the treatment of hepatitis C virus (HCV) infections, is a potent antivira

173 elaprevir-an FDA-approved drug used to treat hepatitis C virus (HCV) infections-as a potent antiviral

174 services, has contributed to a sharp rise in hepatitis C virus (HCV) infections.

175 ations and scale-up scenarios of combination hepatitis C virus (HCV) interventions for exhaustive tes

176 The hepatitis C virus (HCV) IRES binds eukaryotic translatio

177 Hepatitis C virus (HCV) is a blood borne pathogen mostly

178 Hepatitis C virus (HCV) is a highly variable pathogen th

179 Advanced liver disease due to hepatitis C virus (HCV) is a leading cause of human immu

180 tions for HCV vaccine development.IMPORTANCE Hepatitis C virus (HCV) is a leading cause of liver-rela

181 An effective vaccine for hepatitis C virus (HCV) is a major unmet need, and it re

182 The quantification of hepatitis C virus (HCV) is essential for the management

183 Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) is highly effective.

184 The E2 glycoprotein of hepatitis C virus (HCV) is the major target of broadly n

185 Hepatitis C virus (HCV) is the most common bloodborne pa

186 Hepatitis C virus (HCV) is the most common chronic blood

187 Sexual transmission of hepatitis C virus (HCV) is uncommon, yet documented amon

188 rals (DAAs) has transformed the landscape of hepatitis C virus (HCV) management.

189 Hepatitis C virus (HCV) may increase pulmonary hypertens

190 The hepatitis C virus (HCV) nonstructural protein 5A (NS5A)

191 The discovery of a pan-genotypic hepatitis C virus (HCV) NS3/4A protease inhibitor based

192 We conducted a retrospective cohort study of hepatitis C virus (HCV) patients who achieved SVR with D

193 pment of successful commercial drugs against hepatitis C virus (HCV) polymerase and HIV-1 reverse tra

194 Despite high hepatitis C virus (HCV) prevalence, opioid use disorder

195 rom high-income countries suggest increasing hepatitis C virus (HCV) prevalence/incidence among human

196 cost of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) prompted many payers to restrict

197 ersible-covalent inhibitor that binds to the hepatitis C virus (HCV) protease active site is conjugat

198 ors, and social determinants associated with hepatitis C virus (HCV) reinfection following DAA therap

199 Hepatitis B virus (HBV) and hepatitis C virus (HCV) remain, at present, the most imp

200 he development of a prophylactic vaccine for hepatitis C virus (HCV) remains a global health challeng

201 .IMPORTANCE The development of a vaccine for hepatitis C virus (HCV) remains a global health challeng

202 Hepatitis C virus (HCV) remains a significant public hea

203 Hepatitis C virus (HCV) remains endemic among people who

204 The restricted host tropism of hepatitis C virus (HCV) remains incompletely understood,

205 Clearance of hepatitis C virus (HCV) results in rapid changes in meta

206 We analyzed post-treatment hepatitis C virus (HCV) RNA levels from 330 subjects who

207 We performed hepatitis C virus (HCV) RNA screening among all men who

208 S Preventive Services Task Force (USPSTF) of hepatitis C virus (HCV) screening found interferon-based

209 Hepatitis C virus (HCV) screening is critical to HCV eli

210 r demographic characteristics, behavior, and hepatitis C virus (HCV) seropositivity assessed the rela

211 Hepatitis C virus (HCV) testing and treatment uptake in

212 Hepatitis C virus (HCV) testing in persons born from 194

213 e NS5A inhibitors underpin hugely successful hepatitis C virus (HCV) therapy.

214 Understanding hepatitis C virus (HCV) transmission among people who in

215 Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12

216 fore and after widespread direct-acting anti-hepatitis C virus (HCV) treatment.

217 he effects of interferon-based therapies for hepatitis C virus (HCV) upon the risk of diabetes are co

218 Treatment for hepatitis C virus (HCV) with direct-acting antivirals (D

219 Some people living with hepatitis C virus (HCV) with sustained virological respo

220 rary 2019, 532 individuals were screened for hepatitis C virus (HCV), 180 tested HCV antibody positiv

221 V.IMPORTANCE Development of vaccines against hepatitis C virus (HCV), a major cause of cirrhosis and

222 costs and disruptions in treatment for HIV, hepatitis C virus (HCV), and drug abuse.

223 mark of a protective immune response against hepatitis C virus (HCV), associated with spontaneous vir

224 on-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV), in which an N-benzyl boronic ac

225 the existence of established treatments for hepatitis C virus (HCV), more effective means of prevent

226 Chronic hepatitis B virus (HBV), hepatitis C virus (HCV), nonalcoholic fatty liver diseas

227 Human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients are at high

228 By deciphering mechanistic aspects of hepatitis C virus (HCV)-host interactions, one could dis

229 The mechanisms of chronic hepatitis C virus (HCV)-induced liver fibrosis and hepat

230 ecies, in CD33(+) myeloid cells derived from hepatitis C virus (HCV)-infected patients.

231 milarity to eIF3 recognizing motifs found in hepatitis C virus (HCV)-like IRESs, suggesting mechanist

232 Risk factors for DGF in the hepatitis C virus (HCV)-negative recipient population in

233 irrhosis (CTP 7-9) in patients with advanced hepatitis C virus (HCV)-related cirrhosis.

234 Exhaustion of Hepatitis C Virus (HCV)-specific T cells and abnormal B

235 Outcomes following hepatitis C virus (HCV)-viremic heart transplantation in

236 Hepatitis C virus (HCV)-viremic organs are underutilized

237 he context of its activity as a receptor for hepatitis C virus (HCV).

238 r is an aryloxazole-based entry inhibitor of hepatitis C virus (HCV).

239 t recognizes the E2 envelope glycoprotein of hepatitis C virus (HCV).

240 ject drugs in the United States have chronic hepatitis C virus (HCV).

241 ika virus (ZIKV), West Nile virus (WNV), and hepatitis C virus (HCV).

242 on individuals are chronically infected with hepatitis C virus (HCV).

243 nd outcome of liver transplantation (LT) for hepatitis C virus (HCV).

244 s (NASH), alcoholic liver disease (ALC), and hepatitis C virus (HCV).

245 tion of retroviruses, hepatitis B virus, and hepatitis C virus (HCV).

246 e activation of CD81 [the portal of entry of hepatitis C virus (HCV)] by agonistic antibody results i

247 st common etiology of liver disease (LD) was hepatitis C virus (N = 48) and nonalcoholic steatohepati

248 is of human immunodeficiency virus (HIV) and hepatitis C virus .

249 responding to chronic viral infections (HIV, hepatitis C virus [HCV], Epstein-Barr virus [EBV], and c

250 The WHO elimination strategy for hepatitis C virus advocates scaling up screening and tre

251 f hepatitis C viral inhibitors and comparing hepatitis C virus and coronavirus replication, we previo

252 targets of interest (Plasmodium falciparum, Hepatitis C virus and T-cells) to demonstrate the value

253 e 1, Human Immunodeficiency Virus type 1 and Hepatitis C Virus as well as in the inflammatory conditi

254 ses, decompensated cirrhosis, cirrhosis, and hepatitis C virus compared to patients with chronic HBV.

255 Hepatitis C virus cure in coinfection brings monocyte ac

256 ection with tuberculosis and HIV and HIV and hepatitis C virus exist.

257 nstable housing, previous incarceration, and hepatitis C virus exposure.

258 merase that catalyzes the replication of the hepatitis C virus genome.

259 l lines as well as antiviral effects against hepatitis C virus in the replicon assay.

260 njection drug use (4.89; 1.95-12.26), active hepatitis C virus infection (3.39; 1.10-12.26), and iden

261 Hepatitis C virus infection (OR, 15.84; 95% confidence i

262 ansfusions throughout her life, leading to a hepatitis C virus infection (which was treated, achievin

263 sting for race/ethnicity, age, HIV load, and hepatitis C virus infection and controlling for multipli

264 Screening for hepatitis C virus infection in adolescents and adults: U

265 Eliminating the burden of disease caused by hepatitis C virus infection is proving difficult, despit

266 Approximately 29.6% prevalence of Hepatitis C virus infection observed among inmates studi

267 Poverty, injection drug use, and hepatitis C virus infection were also associated.

268 e II diabetes (T2D) may worsen the course of hepatitis C virus infection with a greater risk of liver

269 g sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivi

270 eding in persons with chronic hepatitis B or hepatitis C virus infection.

271 emic has been associated with an increase in hepatitis C virus infections among women of childbearing

272 of treating human immunodeficiency virus and hepatitis C virus infections, ID physicians have unique

273 e to an effective vaccine for HCV.IMPORTANCE Hepatitis C virus infects approximately 1% of the world'

274 identification of compounds that target the hepatitis C virus internal ribosome entry site (IRES) an

275 HCC) development in alcohol Western diet-fed hepatitis C virus NS5A Tg mice with hepatocyte-specific

276 even when under antiretroviral therapy), and hepatitis C virus or those of mice with lymphocytic chor

277 allosteric inhibitors have been reported for hepatitis C virus RdRp, few have been described for DENV

278 The hepatitis C virus RNA-dependent RNA polymerase NS5B is r

279 ound kidney disease, dialysis vintage, donor hepatitis C virus status, cardiovascular diseases, panel

280 Hepatitis C virus SVR decreased monocyte interferon gene

281 We adapted a previous model of hepatitis C virus transmission, treatment, and disease p

282 % of diagnosed cases) were initiated on anti-hepatitis C virus treatment in the Veterans Affairs heal

283 SIV), irrespective of virus tropism, but not hepatitis C virus, adenovirus 5 (ADV5), Zika virus, and

284 f the mechanisms by which hepatitis B virus, hepatitis C virus, alcohol, fatty liver disease, and oth

285 coronavirus, human immunodeficiency virus 1, hepatitis C virus, and Japanese encephalitis virus.

286 The glycoproteins of hepatitis C virus, E1E2, are unlike any other viral fusi

287 , e.g., SARS-CoV-2, influenza, dengue fever, hepatitis C virus, HIV, rotavirus and Zika virus.

288 es by diagnosis of hepatocellular carcinoma, hepatitis C virus, nonalcoholic steatohepatitis, or Medi

289 viral agents, there has been a rapid rise in hepatitis C virus-infected (HCV+) heart transplantation.

290 ent hepatocellular carcinoma (HCC) in 15,059 hepatitis C virus-infected patients with advanced liver

291 Hepatitis C virus-positive (HCV+) kidney transplant (KT)

292 Solid organ transplantation from hepatitis C virus-positive (HCV-positive) deceased donor

293 ration of median wait times, availability of hepatitis C virus-positive organs, and degree of liver d

294 rapy, and, if applicable, elimination of the hepatitis C virus.

295 proteins of human immunodeficiency virus and hepatitis C virus.

296 lar carcinoma (HCC) in patients with chronic hepatitis C virus; however, their impact in patients wit

297 ridae family, including Zika, West Nile, and hepatitis C viruses.

298 Those reactive for hepatitis C were further tested for HCV RNA genotyping.

299 o incorporate a detailed cascade of care for hepatitis C with cost data on diagnostics and hepatitis

300 Georgia has a high prevalence of hepatitis C, with 5.4% of adults chronically infected.